REGN Expense Breakdown
REGENERON PHARMACEUTICALS, INC. (REGN). Quarter ended 2026-06-30 · each product line is listed as filed.
- 2026-06-30: Products $360.70M; Collaboration and Contract Manufacturing $215.80M.
- 2025-06-30: Products $275.60M; Collaboration and Contract Manufacturing $254.60M.
Expenses by product
Cost of sales: each quarter (3 month)
| Quarter end | Products | Collaboration and Contract Manufacturing |
|---|---|---|
| 2026-06-30 | $360.70M | $215.80M |
| 2025-06-30 | $275.60M | $254.60M |
Research and development: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $1.63B |
| 2025-06-30 | $1.42B |
Research And Development Expense Reimbursements: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | -$26.20M |
| 2025-06-30 | -$42.30M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |